Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

Person › Details

John Dawson (Oxford Biomedica plc (LSE: OXB))

Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)

	Organisation	Oxford Biomedica plc (LSE: OXB)
	Group	Oxford Biomedica (Group)
	Former/major organisation	Cephalon Europe
	Today	Teva (Group)
	Group	Teva (Group)
	Product	TroVax®
	Product 2	ProSavin®

Record changed: 2020-11-10

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for John Dawson

[1] PhoreMost Ltd.. (11/9/20). "Press Release: PhoreMost and Oxford Biomedica Enter Gene Therapy Discovery Collaboration". Cambridge & Oxford....
[2] Oxford BioMedica plc. (9/1/20). "Press Release: Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222". Oxford....
[3] Oxford Biomedica plc. (6/8/20). "Press Release: Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre". Oxford....
[4] Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford....
[5] Oxford Biomedica plc. (3/18/20). "Press Release: Oxford BioMedica Signs License & Clinical Supply Agreement with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for LentiVector Platform for CAR-T and TCR-T Therapeutics". Oxford....
[6] Oxford Biomedica plc. (5/28/19). "Press Release: Oxford BioMedica Announces Strategic Investment by Novo Holdings A/S". Oxford....
[7] Oxford Biomedica plc. (3/14/19). "Press Release: Oxford Biomedica plc Preliminary Results for the Year Ended 31 December 2018". Oxford....
[8] Oxford Biomedica plc. (2/7/19). "Press Release: Oxford Biomedica Provides Update on Programmes Outlicensed to Sanofi". Oxford....
[9] Oxford Biomedica plc. (11/23/18). "Press Release: Oxford BioMedica Announces New Digital Framework Initiative to Streamline the Production of Next-generation Medicines with Cash Injection from Innovate UK". Oxford....
[10] Boehringer Ingelheim. (8/6/18). "Press Release: Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis". Ingelhei...

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]